LTZ Therapeutics, a Redwood City, CA- and Shenzen, China-based immunotherapy-focused biotech company, closed its Series A financing of over $20m.
This round, which brought total funding to approximately $50m, was led by new investor Lapam Capital with participation from GL Ventures, K2 Venture Partners and Shunwei Capital.
The company intends to use the funds to advance the development of its Myeloid Engager pipeline to treat cancer and autoimmune diseases. Proceeds from the financing will be used to accelerate development of LTZ’s pipeline, supporting the company’s Investigational New Drug (IND) process, initiating the Phase 1 clinical study of LTZ’s lead asset LTZ-301 as well as the IND-enabling work of its second asset, LTZ-232. LTZ Therapeutics will also use the new capital to further advance other programs in discovery and to expand its team.
Led by Robert Li, Ph.D., Founder and CEO, LTZ Therapeutics is an immunotherapy-focused biotech company pursuing the development of novel therapies, with its novel Myeloid Engager Platform, to improve clinical outcomes in patients with cancer and autoimmune diseases. With main operations in Redwood City, California and Shenzhen, China as well as a team out of Heidelberg Germany, LTZ is dedicated to developing immunotherapies capable of overcoming resistance and boosting anti-tumor immunity based on reverse translational science and emerging disease biology of tumor microenvironment.
FinSMEs
30/07/2024